DSM, private equity firm, buy drugmaker Patheon



Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

AMSTERDAM (AP) - Dutch chemicals maker Royal DSM NV and private equity firm JLL are teaming up to buy Canada's Patheon Inc. for $195 million (145 million euros) so they can combine it with DSM's pharmaceuticals arm and then spin off the new combination as a separate company.

Under the deal announced Tuesday, JLL will contribute $489 million to the new company, with the funds used to buy Patheon and pay DSM $200 million. After the deal, JLL will own 51 percent of the new entity, and DSM will own 49 percent.

Patheon's managers, who own a majority of their company, have agreed to the firms' $9.32 per share takeover offer. That's a 64 percent premium to Patheon's closing price Monday.

(Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)

Most recent Business & Tech stories

Related topics

Business & Tech

SIGN UP FOR THE KSL.COM NEWSLETTER

Catch up on the top news and features from KSL.com, sent weekly.
By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

KSL Weather Forecast